Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct 16, 2025-

First patient dosed in Adicet’s trial of ADI-001 in RA - BioTuesdays

Adicet Bio (NASDAQ: ACET) has announced that the first patient has been dosed in its Phase 1 clinical trial evaluating ADI-001 in treatment-refractory rheumatoid arthritis (RA). The company’s Phase 1 study is designed to evaluate the safety, tolerability and preliminary efficacy of ADI-001 in patients with treatment-refractory RA. ADI-001 was granted fast track designation by the FDA for the potential treatment of relapsed/refractory class III o…